Skip to main content
Premium Trial:

Request an Annual Quote

Bruker Announces Promotions in Finance, Business Development Areas

NEW YORK, May 22 - Bruker Daltonics said Tuesday it had appointed John Hulburt as chief financial officer and Ulrich Giessmann as vice president in charge of the company's entire US Maldi-TOF and ESI-TOF business.

Hulburt was previously was Bruker Daltonics’ treasurer, controller, and chief accounting officer. Giessmann previously managed the development of the Billerica, Mass.-based company’s BioTOF ESI-TOF technology.

"I am exited about the opportunity to develop and manufacture products in a way that best meets the needs of our life-science customers," Giessmann said in a statement "I look forward to contribute my experience in engineering and production management to our time-of-flight mass spectrometry systems."

Giessmann has a Ph.D. in physical chemistry from the University of Bonn in Germany. He was previously R&D manager of Finnigan MAT in Germany, where he was responsible for the development of their first MALDI-TOF instrument. Giessmann joined Bruker two years ago.

Hulburt has been with Bruker for the past year. Previously he worked for Ernst & Young and Arthur Andersen.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.